Responsive image

Common name

2-(methylamino)ethanol

IUPAC name

2-(methylamino)ethanol

SMILES

C(CO)NC

Common name

2-(methylamino)ethanol

IUPAC name

2-(methylamino)ethanol

SMILES

C(CO)NC

INCHI

InChI=1S/C3H9NO/c1-4-2-3-5/h4-5H,2-3H2,1H3

FORMULA

C3H9NO

Responsive image

Common name

2-(methylamino)ethanol

IUPAC name

2-(methylamino)ethanol





Molecular weight

75.110

clogP

-0.544

clogS

-0.422

Frequency

0.0089





HBond Acceptor

1

HBond Donor

2

Total Polar
Surface Area

32.26

Number of Rings

0

Rotatable Bond

2

Drug ID Common name Structure CAS Compound class Therapeutic area
FDBD00092 Dofetilide Responsive image Anti-Arrhythmia Agents; Potassium Channel Blockers; Cardiovascular System; Antiarrhythmics, Class III; Antiarrhythmics, Class I and Iii; Cardiac Therapy; Antiarrythmics, Class I and Iii; CYP3A4 Inhibitors; For the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm.
FDBD00215 Ethambutol Responsive image Antitubercular Agents; Antimycobacterials; Antiinfectives for Systemic Use; Drugs for Treatment of Tuberculosis; For use, as an adjunct, in the treatment of pulmonary tuberculosis.
FDBD00268 Phenylephrine Responsive image Vasoconstrictor Agents; Sympathomimetics; Adrenergic alpha-1 Receptor Agonists; Cardiotonic Agents; Mydriatics; Nasal Decongestants; Respiratory System; Ophthalmologicals; Sensory Organs; Nasal Preparations; Cardiovascular System; Cardiac Therapy; Adrenergic and Dopaminergic Agents; Cardiac Stimulants Excl. Cardiac Glycosides; Sympathomimetics, Plain; Nasal Decongestants for Systemic Use; Sympathomimetics Excl. Antiglaucoma Preparations; Mydriatics and Cycloplegics; Sympathomimetics Used as Decongestants; Decongestants and Antiallergics; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; Phenylephrine is mainly used to treat nasal congestion, but may also be useful in treating hypotension and shock, hypotension during spinal anaesthesia, prolongation of spinal anaesthesia, paroxysmal supraventricular tachycardia, symptomatic relief of external or internal hemorrhoids, and to increase blood pressure as an aid in the diagnosis of heart murmurs.
FDBD00291 Rosiglitazone Responsive image Hypoglycemic Agents; Drugs Used in Diabetes; Alimentary Tract and Metabolism; Thiazolidinediones; Blood Glucose Lowering Drugs, Excl. Insulins; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C8 Inducers; CYP2A6 Inhibitors; CYP2A6 Inhibitors (strong); CYP2A6 Inhibitors (moderate); CYP2A6 Inducers; CYP2A6 Inducers (strong); CYP2D6 Inducers; CYP2D6 Inducers (strong); Rosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
FDBD00324 Dipivefrin Responsive image Adrenergic Agonists; Ophthalmics; Ophthalmologicals; Sensory Organs; Antiglaucoma Preparations and Miotics; Sympathomimetics in Glaucoma Therapy; Beta2 Agonists; Alpha2 Agonists; Dipivefrin is a prodrug which is used as initial therapy for the control of intraocular pressure in chronic open-angle glaucoma.
FDBD00533 Epinephrine Responsive image Vasoconstrictor Agents; Sympathomimetics; Bronchodilator Agents; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Agonists; Mydriatics; Adrenergic beta-Agonists; Blood and Blood Forming Organs; Respiratory System; Ophthalmologicals; Sensory Organs; Antihemorrhagics; Drugs for Obstructive Airway Diseases; Alimentary Tract and Metabolism; Stomatological Preparations; Nasal Preparations; Cardiovascular System; Antiglaucoma Preparations and Miotics; Cardiac Therapy; Adrenergic and Dopaminergic Agents; Cardiac Stimulants Excl. Cardiac Glycosides; Adrenergics, Inhalants; Sympathomimetics, Plain; Sympathomimetics in Glaucoma Therapy; Local Hemostatics; Alpha- and Beta-Adrenoreceptor Agonists; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP2C9 Inducers; CYP3A4 Inhibitors; Beta2 Agonists; Alpha2 Agonists; Used to treat anaphylaxis and sepsis. Also one of the body's main adrenergic neurotransmitters.
FDBD00566 Amprenavir Responsive image Anti-HIV Agents; Antibiotics, Antitubercular; Protease Inhibitors; HIV Protease Inhibitors; Antiinfectives for Systemic Use; Direct Acting Antivirals; Antivirals for Systemic Use; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inhibitors; CYP2B6 Inhibitors (strong); CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP3A4 Inhibitors; Combined Inhibitors of CYP3A4 and P-glycoprotein; For the treatment of HIV-1 infection in combination with other antiretroviral agents.
FDBD00793 Salmeterol Responsive image Sympathomimetics; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Respiratory System; Drugs for Obstructive Airway Diseases; Selective Beta-2-Adrenoreceptor Agonists; Adrenergics, Inhalants; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inducers; CYP3A4 Inhibitors; Beta2 Agonists; For the treatment of asthma and chronic obstructive pulmonary disease (COPD).
FDBD00829 Dipyridamole Responsive image Platelet Aggregation Inhibitors; Phosphodiesterase Inhibitors; Vasodilator Agents; Antithrombotic Agents; Blood and Blood Forming Organs; Platelet Aggregation Inhibitors Excl. Heparin; For as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement and also used in prevention of angina.
FDBD00923 Atazanavir Responsive image Anti-HIV Agents; Protease Inhibitors; HIV Protease Inhibitors; Antiinfectives for Systemic Use; Direct Acting Antivirals; Antivirals for Systemic Use; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inducers; CYP3A4 Inhibitors; Combined Inhibitors of CYP3A4 and P-glycoprotein; Used in combination with other antiretroviral agents for the treatment of HIV-1 infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a substantial risk for HIV transmission.
26 , 3
FRAGNAME PDBID SIMILIRITY XSCORE SMILE HAC
2reg_ligand.mol2 2reg 1 -6.35 C(C[N+](C)(C)C)O 8
2ha3_ligand.mol2 2ha3 1 -5.88 C(C[N+](C)(C)C)O 8
3feg_ligand_4_121.mol2 3feg 1 -5.69 OCC[N+](C)(C)C 7
3c2u_ligand_2_18.mol2 3c2u 1 -5.65 C([NH2+]C)CO 5
130 , 14